• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

6'-叠氮基己-2'-炔-δ8-四氢大麻酚在大麻素受体上的部分激动剂-反向激动剂特性的结构决定因素

Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.

作者信息

Ross R A, Gibson T M, Stevenson L A, Saha B, Crocker P, Razdan R K, Pertwee R G

机构信息

Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.

出版信息

Br J Pharmacol. 1999 Oct;128(3):735-43. doi: 10.1038/sj.bjp.0702836.

DOI:10.1038/sj.bjp.0702836
PMID:10516656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1571677/
Abstract
  1. We have extended previous investigations of four analogues of Delta8-tetrahydrocannabinol (Delta8-THC): 6'-azidohex-2'-yne-Delta8-THC (O-1184), 6'-azidohex-cis-2'-ene-Delta8-THC (O-1238) and octyl-2'-yne-Delta8-THC (O-584) and its 1-deoxy-analogue (O-1315). 2. O-1184, O-1238 and O-584 displaced [3H]-CP55940 from specific binding sites on Chinese hamster ovary (CHO) cell membranes expressing CB1 or CB2 cannabinoid receptors, with pKi values of 8.28 to 8.45 (CB1) and 8.03 to 8.13 (CB2). The pKi values of O-1315 were significantly less, 7.63 (CB1) and 7.01 (CB2). 3. All the analogues inhibited forskolin-stimulated cyclic AMP production by CB1-transfected CHO cells (pEC50=9.16 to 9.72). Only O-1238 behaved as a full agonist in this cell line. 4. In mouse vasa deferentia, O-1238 inhibited electrically-evoked contractions (pEC50=10.18 and Emax=70.5%). Corresponding values for O-1184 were 9.08 and 21.1% respectively. At 1 nM, O-1184 produced surmountable antagonism of the cannabinoid receptor agonist, CP55940. However, at 0.1 nM, O-1184 did not attenuate CP55940-induced inhibition of cyclic AMP production by CB1-transfected CHO cells. 5. In CB2-transfected CHO cells, cyclic AMP production was inhibited by CP55940 (pEC50=8.59), enhanced by O-1184 and O-584 (pEC50=8.20 and 6.86 respectively) and not significantly affected by O-1238 or O-1315. 6. At 100 nM, O-1184 and O-1238 produced surmountable antagonism of CP55940 in CB2 cells, decreasing the pEC50 of CP55940 from 8.61 to 7.42 (O-1184) or from 8. 54 to 7.44 (O-1238). 7. These data support the hypothesis that increasing the degree of unsaturation of the aliphatic side-chain of Delta8-THC analogues has little effect on CB1 or CB2 receptor affinity but can reduce CB1 receptor efficacy and reverse the direction of responses elicited at CB2 receptors.
摘要
  1. 我们扩展了之前对四种δ8-四氢大麻酚(δ8-THC)类似物的研究:6'-叠氮基己-2'-炔-δ8-THC(O-1184)、6'-叠氮基己-顺-2'-烯-δ8-THC(O-1238)、辛基-2'-炔-δ8-THC(O-584)及其1-脱氧类似物(O-1315)。2. O-1184、O-1238和O-584从表达CB1或CB2大麻素受体的中国仓鼠卵巢(CHO)细胞膜上的特异性结合位点取代了[3H]-CP55940,其pKi值在CB1为8.28至8.45,在CB2为8.03至8.13。O-1315的pKi值明显较低,在CB1为7.63,在CB2为7.01。3. 所有类似物均抑制CB1转染的CHO细胞中福斯高林刺激的环磷酸腺苷(cAMP)产生(pEC50 = 9.16至9.72)。在该细胞系中只有O-1238表现为完全激动剂。4. 在小鼠输精管中,O-1238抑制电诱发的收缩(pEC50 = 10.18,Emax = 70.5%)。O-1184的相应值分别为9.08和21.1%。在1 nM时,O-1184对大麻素受体激动剂CP55940产生可克服的拮抗作用。然而,在0.1 nM时,O-1184并未减弱CP55940诱导的CB1转染的CHO细胞中环磷酸腺苷产生的抑制作用。5. 在CB2转染的CHO细胞中,CP55940抑制环磷酸腺苷产生(pEC50 = 8.59),O-1184和O-584增强环磷酸腺苷产生(pEC50分别为8.20和6.86),而O-1238或O-1315对其无明显影响。6. 在100 nM时,O-1184和O-1238在CB2细胞中对CP55940产生可克服的拮抗作用,使CP55940的pEC50从8.61降至7.42(O-1184)或从8.54降至7.44(O-1238)。7. 这些数据支持以下假设:增加δ8-THC类似物脂肪族侧链的不饱和度对CB1或CB2受体亲和力影响很小,但可降低CB1受体效能并逆转在CB2受体上引发的反应方向。

相似文献

1
Structural determinants of the partial agonist-inverse agonist properties of 6'-azidohex-2'-yne-delta8-tetrahydrocannabinol at cannabinoid receptors.6'-叠氮基己-2'-炔-δ8-四氢大麻酚在大麻素受体上的部分激动剂-反向激动剂特性的结构决定因素
Br J Pharmacol. 1999 Oct;128(3):735-43. doi: 10.1038/sj.bjp.0702836.
2
O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.O-1057,一种具有抗伤害感受特性的强效水溶性大麻素受体激动剂。
Br J Pharmacol. 2000 Apr;129(8):1577-84. doi: 10.1038/sj.bjp.0703245.
3
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.L759633、L759656和AM630在CB1和CB2大麻素受体上的激动剂-反向激动剂特性研究
Br J Pharmacol. 1999 Feb;126(3):665-72. doi: 10.1038/sj.bjp.0702351.
4
Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.豚鼠前脑和小肠中大麻素结合位点的比较。
Br J Pharmacol. 1998 Nov;125(6):1345-51. doi: 10.1038/sj.bjp.0702204.
5
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.有证据表明植物大麻素Δ9-四氢大麻酚是一种大麻素CB1和CB2受体拮抗剂。
Br J Pharmacol. 2005 Dec;146(7):917-26. doi: 10.1038/sj.bjp.0706414.
6
The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.精神活性植物大麻素Δ9-四氢大麻酚在小鼠体内受到Δ8-和Δ9-四氢大麻二酚的拮抗作用。
Br J Pharmacol. 2007 Mar;150(5):586-94. doi: 10.1038/sj.bjp.0707124. Epub 2007 Jan 22.
7
3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor.3-(1',1'-二甲基丁基)-1-脱氧-δ8-四氢大麻酚及相关化合物:CB2受体选择性配体的合成
Bioorg Med Chem. 1999 Dec;7(12):2905-14. doi: 10.1016/s0968-0896(99)00219-9.
8
Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations.6'-氰基己-2'-炔-δ8-四氢大麻酚在两种离体组织制剂中的激动剂-拮抗剂特性研究
Eur J Pharmacol. 1996 Nov 14;315(2):195-201. doi: 10.1016/s0014-2999(96)00631-0.
9
(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.(-)-Δ9-四氢大麻酚可拮抗外周大麻素受体介导的腺苷酸环化酶抑制作用。
J Biol Chem. 1996 Apr 26;271(17):9902-5. doi: 10.1074/jbc.271.17.9902.
10
Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).神经元大麻素受体(CB1)强效和选择性激动剂的合成与表征
J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33.

引用本文的文献

1
Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.大麻素受体药理学进展:从受体结构洞察到配体发现
Acta Pharmacol Sin. 2025 Feb 5. doi: 10.1038/s41401-024-01472-9.
2
Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from and non-cannabis phytomolecules.来自大麻和非大麻植物分子的大麻素副产物对1型大麻素受体活性的调节。
Front Pharmacol. 2022 Aug 26;13:956030. doi: 10.3389/fphar.2022.956030. eCollection 2022.
3
Epidemiology of Δ8THC-Related Carcinogenesis in USA: A Panel Regression and Causal Inferential Study.美国与 Δ8THC 相关的致癌流行病学:面板回归和因果推断研究。
Int J Environ Res Public Health. 2022 Jun 23;19(13):7726. doi: 10.3390/ijerph19137726.
4
Congenital anomaly epidemiological correlates of Δ8THC across USA 2003-16: panel regression and causal inferential study.2003 - 2016年美国各地Δ8四氢大麻酚的先天性异常流行病学关联:面板回归与因果推断研究
Environ Epigenet. 2022 May 17;8(1):dvac012. doi: 10.1093/eep/dvac012. eCollection 2022.
5
In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa.大麻中二大麻素的体外和体内药理学活性。
Sci Rep. 2020 Nov 23;10(1):20405. doi: 10.1038/s41598-020-77175-y.
6
Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.吲哚美辛增强1型大麻素受体信号传导。
Front Mol Neurosci. 2019 Oct 18;12:257. doi: 10.3389/fnmol.2019.00257. eCollection 2019.
7
Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.绘制大麻素1受体变构位点:新型、强效且不可逆结合探针GAT100的关键分子决定因素和信号特征
ACS Chem Neurosci. 2016 Jun 15;7(6):776-98. doi: 10.1021/acschemneuro.6b00041. Epub 2016 Apr 25.
8
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).用于绘制大麻素1受体变构位点的新型亲电和亲光亲和共价探针
J Med Chem. 2016 Jan 14;59(1):44-60. doi: 10.1021/acs.jmedchem.5b01303. Epub 2015 Nov 28.
9
Sulfated phenolic compounds from Limonium caspium: Isolation, structural elucidation, and biological evaluation.来自里海补血草的硫酸化酚类化合物:分离、结构解析及生物学评价。
Fitoterapia. 2015 Jul;104:80-5. doi: 10.1016/j.fitote.2015.05.017. Epub 2015 May 27.
10
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects.植物大麻素Δ⁹-四氢大麻酚酸(Δ⁹-tetrahydrocannabivarin)可通过5-羟色胺1A(5-HT₁A)受体发挥作用,产生抗精神病作用。
Br J Pharmacol. 2015 Mar;172(5):1305-18. doi: 10.1111/bph.13000.

本文引用的文献

1
Pharmacology of cannabinoid receptor ligands.大麻素受体配体的药理学
Curr Med Chem. 1999 Aug;6(8):635-64.
2
An investigation into the structural determinants of cannabinoid receptor ligand efficacy.大麻素受体配体效能的结构决定因素研究。
Br J Pharmacol. 1999 Apr;126(7):1575-84. doi: 10.1038/sj.bjp.0702469.
3
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.L759633、L759656和AM630在CB1和CB2大麻素受体上的激动剂-反向激动剂特性研究
Br J Pharmacol. 1999 Feb;126(3):665-72. doi: 10.1038/sj.bjp.0702351.
4
Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine.豚鼠前脑和小肠中大麻素结合位点的比较。
Br J Pharmacol. 1998 Nov;125(6):1345-51. doi: 10.1038/sj.bjp.0702204.
5
Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.SR141716A对人重组大麻素CB1和CB2受体反向激动作用的证据。
Br J Pharmacol. 1998 Jun;124(4):619-22. doi: 10.1038/sj.bjp.0701915.
6
SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.SR 144528,首个强效且选择性的CB2大麻素受体拮抗剂。
J Pharmacol Exp Ther. 1998 Feb;284(2):644-50.
7
Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals.在外周神经末梢存在类CB2大麻素受体的证据。
Eur J Pharmacol. 1997 Nov 19;339(1):53-61. doi: 10.1016/s0014-2999(97)01336-8.
8
Pharmacology of cannabinoid CB1 and CB2 receptors.大麻素CB1和CB2受体的药理学
Pharmacol Ther. 1997;74(2):129-80. doi: 10.1016/s0163-7258(97)82001-3.
9
A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.一种针对中枢大麻素受体的选择性反向激动剂可抑制胰岛素或胰岛素样生长因子1刺激的丝裂原活化蛋白激酶激活。受体/配体相互作用新模型的证据。
J Biol Chem. 1997 Aug 29;272(35):22330-9. doi: 10.1074/jbc.272.35.22330.
10
Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations.6'-氰基己-2'-炔-δ8-四氢大麻酚在两种离体组织制剂中的激动剂-拮抗剂特性研究
Eur J Pharmacol. 1996 Nov 14;315(2):195-201. doi: 10.1016/s0014-2999(96)00631-0.